Hong Kong Stock Movement
ASCLETIS-B fell 11.02%. Based on recent key news:
<ol>
<li>
On December 12, ASCLETIS-B announced the repurchase of 300,000 shares at a cost of approximately HKD 4.3738 million. This move may be interpreted by the market as a lack of confidence in the company's own stock, leading to a decline in share price. Source: Zhitong Finance
</li>
<li>
On December 12, ASCLETIS-B submitted a disclosure report to the Hong Kong Stock Exchange detailing the price range and total amount of the share repurchase. Although repurchases are generally seen as positive news, the market reacted poorly, and the share price continued to decline. Source: Hong Kong Stock Exchange Announcement
</li>
<li>
No other significant news recently. The Hong Kong stock market has seen increased volatility recently, and investors should exercise caution.
</li>
</ol>
Stocks with High Trading Volume in the Industry
CanSino Biologics fell 5.86%. Based on recent key news:
<ol>
<li>
On December 11, CanSino Biologics announced that the FDA approved its global multicenter Phase III trial to study the efficacy and safety of the innovative PD-1/CTLA-4 bispecific antibody cadonilimab in gastric cancer. This trial marks a significant advancement in innovative treatment methods, driving stock price fluctuations.
</li>
<li>
On December 12, CanSino Biologics stated that through efficient breakthrough R&amp;D innovation, it integrates global resources to develop first-class new drugs, providing affordable therapeutic antibodies and continuously creating commercial and social value, becoming a global leading biopharmaceutical company.
</li>
<li>
On December 12, the industry faces risks and uncertainties, including industry conditions, competition, economic factors, drug industry regulation, global healthcare cost control trends, technological advancements, new products, and patent competition, affecting market sentiment. The biopharmaceutical industry's innovation is accelerating, and regulatory risks are increasing.
</li>
</ol>
BeiGene fell 7.15%. Based on recent news:
<ol>
<li>
On December 15, BeiGene recorded a cross-trade of 180,100 shares at HKD 181.15 per share, down 6.9% from the previous closing price, involving HKD 32.63 million, leading to a decline in share price.
</li>
<li>
On December 12, the head of the National Medical Products Administration expressed support for companies to strengthen the layout of innovative drug and device R&amp;D. Under policy-driven conditions, the innovative drug industry has achieved leapfrog development, although the market reaction has been poor in the short term.
</li>
<li>
On December 12, CMB International stated that the proportion of domestic capital holding pharmaceutical stocks through the Stock Connect slightly decreased, while foreign capital holdings remained stable overall. The direction of innovative drug layout remains unchanged, but short-term capital outflows exert pressure on share prices. Changes in pharmaceutical industry policies and capital outflows affect share prices.
</li>
</ol>
Innovent Biologics fell 3.99%. Based on recent news:
<ol>
<li>
On December 12, Innovent Biologics' stock price retreated from a recent high of HKD 99.00, approaching the lower bound of the Bollinger Bands, with shrinking trading volume indicating limited bearish momentum. The downward space for the stock price has significantly narrowed, and the adjustment remains a healthy consolidation within a bullish flag pattern. If the stock price does not fall below HKD 78.60, the upward trend remains intact. Source: Hong Kong 01
</li>
<li>
On December 12, Innovent Biologics launched 17 products, with one new drug application currently under review. This move demonstrates the company's active performance in the market, which may have a positive impact on its stock price. Source: PR Newswire
</li>
<li>
On December 12, Innovent Biologics plans to initiate the Phase III registration trial of Mazdutide to evaluate its effectiveness in treating obesity in adolescents, aiming to address significant clinical needs. This move may enhance market expectations for the company's future growth. Source: RTT News Hong Kong stocks have recently experienced increased volatility, requiring attention to policy changes.
</li>
</ol>
Stocks ranked among the top in industry market capitalization
Kanglongda Biotech-B fell 7.66%. Based on recent key news:
<ol>
<li>
On December 13, Kanglongda's Bodo Trastuzumab won in a head-to-head Phase III clinical study against Roche's HER2 ADC, significantly improving median PFS and consolidating its position in the domestic HER2-positive breast cancer second-line and above treatment. However, the failure to obtain approval for the third-line indication before the importation of drugs has raised market concerns about its future development.
</li>
<li>
On December 12, CICC maintained a buy rating on Kanglongda, with a target price of HKD 550. Analysts generally believe that the stock has a 32.03% upside potential, but the strict requirements for innovative drug approvals may affect its stock performance.
</li>
<li>
On December 14, Hubei Province launched cross-provincial retrieval of medical insurance imaging cloud, promoting medical data sharing. Although this is not directly related to Kanglongda, it reflects the overall innovation trend in the healthcare industry. The strict approval of innovative drugs poses challenges for the industry
</li>
</ol>

01672

ASCLETIS-B fell 11.02%; CanSino Biologics fell 5.86%, with a transaction volume of HKD 937 million; BeiGene fell 7.15%, with a transaction volume of HKD 925 million; Innovent Biologics fell 3.99%, with a transaction volume of HKD 853 million; Kelun-Biotech fell 7.66%, with a market value of HKD 94 billion

Hong Kong Stock Movement: ASCLETIS-B's buyback failed to boost confidence, with the stock price falling 11.02% against the trend